Today: 9 April 2026
Tesla stock pops at the open as robotaxi “prove-it year” talk meets earnings countdown

Tesla stock pops at the open as robotaxi “prove-it year” talk meets earnings countdown

New York, Jan 12, 2026, 09:34 EST — Regular session

Tesla (TSLA.O) shares rose 2.1% to $445.01 in early New York trading on Monday.

The early move keeps the spotlight on a stock that trades as much on expectations for new businesses as on car sales. Investors are trying to map Tesla’s next catalysts onto a market that is quick to punish misses.

That backdrop is noisy this week. Traders are looking to U.S. inflation data due Tuesday and the start of quarterly earnings season for big banks, both of which can jolt rate-sensitive growth names. Investors.com

Chief Executive Elon Musk has framed 2026 as a “prove-it” year, with Tesla facing self-imposed deadlines tied to robotaxis, a purpose-built “Cybercab,” its Optimus humanoid robot and the long-delayed Roadster, Business Insider reported. “I think 2026 is going to be the prove-it year for Tesla’s robotaxi business,” Seth Goldstein, an analyst at Morningstar, told the publication. Business Insider

Tesla said on Jan. 2 it delivered 418,227 vehicles in the fourth quarter and deployed 14.2 gigawatt-hours of energy storage products, a record for deployments. The company also warned that deliveries are only one measure and that quarterly results depend on pricing, costs and other factors. Tesla Investor Relations

A company-compiled consensus of sell-side analysts had penciled in 422,850 fourth-quarter deliveries and 13.4 GWh of energy storage deployments. That put Tesla’s vehicle deliveries about 1% below the estimate, while energy storage ran about 6% above it. Tesla Investor Relations

Other U.S. automakers traded lower. Rivian slid 3.3%, General Motors fell 2.7% and Ford was down 1.3%.

But the next test is Tesla’s guidance. If the January results show another squeeze on profitability in the core car business, or slower progress on autonomy, the stock can turn fast.

For now, traders are watching for any fresh signals on robotaxi rollout — a driverless ride-hailing service — and how quickly a dedicated vehicle like the Cybercab can move from promise to volume production. Tesla is expected to report earnings on Jan. 28 after the market close. nasdaq.com

Stock Market Today

  • Ultragenyx Pharmaceutical Shares Surge 8.1% Weekly Amid Valuation Debate
    April 9, 2026, 2:08 AM EDT. Ultragenyx Pharmaceutical (RARE) shares rose 8.1% last week to $23.15 amid mixed performance, down 1.9% year-to-date and 31.7% over 12 months. The biotech specializes in rare disease treatments, a sector sensitive to clinical trial and regulatory updates. Despite recent gains, the company's long-term returns remain negative. A discounted cash flow (DCF) analysis values Ultragenyx at about $257.43 per share, suggesting it is 91% undervalued based on future free cash flow projections turning positive by 2026. However, actual cash flow remains negative at $501.5 million last year. Investors must weigh DCF optimism against market risks and sector volatility. Ultragenyx scores 4 out of 6 in valuation, indicating some appeal but highlighting areas needing scrutiny.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 09.04.2026

9 April 2026
LIVEMarkets rolling coverageStarted: April 9, 2026, 12:00 AM EDTUpdated: April 9, 2026, 2:11 AM EDT Ultragenyx Pharmaceutical Shares Surge 8.1% Weekly Amid Valuation Debate April 9, 2026, 2:08 AM EDT. Ultragenyx Pharmaceutical (RARE) shares rose 8.1% last week to $23.15 amid mixed performance, down 1.9% year-to-date and 31.7% over 12 months. The biotech specializes in rare disease treatments, a sector sensitive to clinical trial and regulatory updates. Despite recent gains, the company's long-term returns remain negative. A discounted cash flow (DCF) analysis values Ultragenyx at about $257.43 per share, suggesting it is 91% undervalued based on future free cash flow
Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next
Previous Story

Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next

Microsoft stock today: Goldman’s $655 target lands as MSFT edges higher in choppy trade
Next Story

Microsoft stock today: Goldman’s $655 target lands as MSFT edges higher in choppy trade

Go toTop